Latest news with #AccessHealth
Newsweek
29-05-2025
- Health
- Newsweek
Athenahealth CEO on Beating an EHR "Scramble"
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. I was speaking with a dear friend this week who is currently undergoing chemotherapy in Missouri. Over glasses of wine and plates full of pasta, we considered why Americans are so unhealthy. I recited the statistics from the American Cancer Society: 1 in 3 people in the U.S. will receive a cancer diagnosis in their lifetime. My friend, age 86, shook his head and offered a different metric: "When you go to the cancer center, you can't even find a place to park. It's packed." Reflecting on this later, I was struck by the ease with which the numbers rolled off my tongue. His observation—less precise (though I bet if I called the hospital, they'd have the statistics to back it up)—prodded something deeper, something solemn. I couldn't shake the cruel image of an ill patient circling the parking lot again and again, the slow recognition of the issue's scale. It's like that camerawork cliche in movies, where they show one line of enemy fighters, then slowly pan out to reveal a colossal army. It makes a person feel small and helpless, which is the exact opposite of how a patient should feel when seeking medical care. Statistics can feel two-dimensional when they're quoted on internet forums and data reports, but they do have tangible impacts. Patients do notice. I've been researching hospitals' "digital command centers" lately: the physical and virtual spaces where staff use predictive analytics, AI and other advanced technology to make real-time decisions about care coordination. It can feel like a numbers game, medical and technology leaders told me, but as my friend's parking lot anecdote illustrates, those numbers have real effects. Dr. Jennifer Watts, associate chief medical officer of acute care and inpatient operations at Children's Mercy Kansas City, said that her system managed change by keeping the "why" at the center of the digital transformation. The health system wanted to get patients to the right place at the right time and say "yes" when people needed to go there for care. Technology was framed as a means to that end. "There were a lot of things that we went through," Watts said, "but keeping our guiding principles at the forefront allowed people to continue to see where we were going and take some of the emotion of change out of it." I'm excited to bring you the full feature on digital command centers in the June 12 edition of Access Health (by the time you read this, I'll be well on my way to the Medditerannean Sea—so you'll have to wait two weeks for the next installment of the newsletter). But in the meantime, I'll leave you with this story from my reporting. I was speaking with a nurse manager at a hospital that recently launched a virtual nursing program and asked her how patient engagement had been. She told me it had far exceeded expectations, with patients opening up to virtual nurses in ways they rarely did to in-person ones. Patients can sense when nurses are busy or there's high anxiety on the floor, she said. They don't always want to contribute to nurses' to-do lists, even if they have a real need. But patients never see their virtual nurse hustling or bustling. That space creates a sense of time and ease—giving way to a closeness that, ironically, might not be achieved without the screen. Essential Reading UChicago Medicine alerted patients to a data breach involving the third-party vendor Nationwide Recovery Services, which specializes in debt collection. The breach occurred in July 2024, but the health system says it was not notified until April 8, 2025. Patient data including financial account information and Social Security numbers may have been compromised, the health system said Tuesday—but neither UChicago nor Nationwide Recovery Services is aware of any misuse of the information. Average wait times for physician appointments are still on the rise according to a new report from staffing company AMN Healthcare,which examined several specialties across more than a dozen cities. Wait times are up 19 percent since the same survey was last conducted in 2022—and have risen 48 percent since the first edition of the survey in have the longest wait timesof the surveyed specialties: nearly 42 days on average, up 79 percent from 2004. The highest wait time recorded in this report was 231 days (note that the average pregnancy is 280 days).Boston had the highest average wait time at 67 days, while Atlanta had the shortest at 13 days. Seventy-five percent: That's the number of children's hospitals that work to address social barriers to health in their of whether you have kids, pediatric hospitals are vital pillars of American society, working to protect and heal the next generation while preserving the magic of why Newsweek and Statista are proud to announce our third annual ranking of America's Best Children's Hospitals. Click here to view the full list, which features the top 50 hospitals across eight pediatric view our list of America's Best Specialized Hospitals here. This new ranking features the top hospitals for cancer, cardiac, neurologic, orthopedic, endocrine and pulmonary care. Space travel is rocketing into the future, and medicine is working to keep up. My colleague, Senior Autos Editor Eileen Falkenberg-Hall, explored the health challenges that astronauts face and the programs that train aerospace physicians. Pulse Check Bob Segert is the chairman and CEO of athenahealth. Bob Segert is the chairman and CEO of athenahealth. athenahealth Bob Segert is the chairman and CEO of athenahealth, a technology company offering electronic health records, revenue cycle management and patient engagement software. athenahealth's primary customers are outpatient, ambulatory care practices—it supports about one fifth of community health centers (CHCs) and a quarter of free clinics across the U.S., according to Segert. These organizations serve about 30 million Americans across all 50 states but are typically under-resourced compared to their counterparts at major health systems. The company launched athenaone for CHCs last week, expanding its AI-powered platform with specific features for local clinics. Previously, the software was rolled out to women's health, urgent care, behavioral health and orthopedic practices, and athenaone for ambulatory surgery centers is expected later this year. On the heels of that announcement, I connected with Segert for a pulse check. Editor's Note: Some responses have been lightly edited for length. athenahealth announced that "value-based care support" will be embedded in its new solution for CHCs. Could you expand on that offering? What can customers expect, exactly? When you look at community health centers, they really provide holistic, whole-person care: all the way from primary care-type services, through mental health, through dental services. Part of what the CHCs are trying to do is improve the care of the populations that they serve. And key to that is value-based care techniques around population health management, care coordination and care management, as well as their specific UDS [uniform data system] reporting, which is the quality reporting required for CHCs. Our value-based care services enable all those things. It enables health centers to be able to have a longitudinal view of their populations. Using risk management tools and population assessment tools as part of our overall pop[ulation] health module, it allows them to do care coordination and care planning through the tools that are embedded within athenaone, and it allows them to do UDS reporting and make sure that they're getting reimbursed and they can actually meet the regulatory requirements that they have as part of the federal funding that they receive in their business. It's really an integrated, holistic approach to value-based care that allows them to be able to understand the full health of the patient. One critique of EHRs is that it can be challenging to see that longitudinal view of a patient's care journey. How does athenahealth paint that picture across a clear, easy interface for clinicians? It's really foundationally the way athena was built. We built open architecture, open ecosystem from the start, with full read-write APIs across almost every data attribute within our software. And we use those APIs ourselves: So whereas other [solution providers] have built on premise-based systems, where they've had to try to scramble to open up their content, we were actually built [as an] open ecosystem. That's a massive advantage across our SaaS-based platform—which is another key thing, we're one version to code. Every single one of the providers that uses athena is on the same platform. Some of our competitors may have an on-premise system that may not have been upgraded for the last five, six or seven years. When we upgrade athena every night (sometimes, for security reasons or other maintenance reasons), and three formal times a year, every single practice gets the new code, and they don't have the option not to take it. So that means that we're current. We're using these open APIs. We're bringing the data in. We have a common snowflake-based data lake. It allows us to create this longitudinal patient record. We have a unique patient ID for every patient, so Alexis, if you are at an athena practice and you consented, you could allow any one of your practices to share that athena data with the other practices on a theme that you see, and it would have one single view. Our unique architecture, the way we're built, it allows us to be so nimble and agile with regard to patient record sharing and of holistic patient information in the chart. C-Suite Shuffles Tom Cowhey is the new CFO of athenahealth , effective June 9. He most recently served as executive vice president and CFO of CVS Health, and previously held the same title at Surgery morning of the announcement, Segert, athenahealth's CEO, told me: "One of the things that's so exciting about Tom is not only that he's a good human being and a great leader, but that he's seen athenahealth from a lot of different angles. ... He really understands our business, across the spectrum of it."Cowhey's former employers, CVS Health and Surgery Partners, are athena clients—so he has engaged with the software from a user perspective. He also worked at Aetna and can provide valuable insight to the insurance side of the business as athena has a "burgeoning" payer business, Segert added. is the , effective June 9. He most recently served as executive vice president and CFO of CVS Health, and previously held the same title at Surgery morning of the announcement, Segert, athenahealth's CEO, told me: "One of the things that's so exciting about Tom is not only that he's a good human being and a great leader, but that he's seen athenahealth from a lot of different angles. ... He really understands our business, across the spectrum of it."Cowhey's former employers, CVS Health and Surgery Partners, are athena clients—so he has engaged with the software from a user perspective. He also worked at Aetna and can provide valuable insight to the insurance side of the business as athena has a "burgeoning" payer business, Segert added. CVS Health has some news of its own after naming Dr. Ravi Patel its vice president and chief health informatics officer for health care delivery. He spent the last 11 months, roughly, as senior vice president of service operations at Oak Street Health—which CVS acquired in 2023. has some news of its own after naming its for health care delivery. He spent the last 11 months, roughly, as senior vice president of service operations at Oak Street Health—which CVS acquired in 2023. NYC Health + Hospitals selected Dr. Anitha Srinivasan to lead its Metropolitan Hospital as chief medical officer. She currently serves as Metropolitan's director of perioperative services and will become the hospital's first female CMO when she takes the reins on June 1, according to a news release from the health system. Executive Edge Dr. Adrienne Boissy is the chief medical officer of Qualtrics. Dr. Adrienne Boissy is the chief medical officer of Qualtrics. Qualtrics Dr. Adrienne Boissy is the chief medical officer of Qualtrics and the former chief experience officer of Cleveland Clinic, where she still serves as a staff neurologist and multiple sclerosis specialist. Boissy is full of great tips—like wearing the same pair of butterfly earrings each day, both to bring some sparkle into "boardrooms that are serious and gray" and to avoid dedicating any "brain power" to changing them. During our conversation last week, she shared the concept of a "joy pie": like a strategic plan, but for yourself. Here's her advice to other busy executives and physicians looking to redefine their priorities: "Given that I've worn some executive hats and leadership hats and practice hats, a couple years ago, I decided I needed to do my own personal strategic plan. I found that my locus of control was more external—what job title I had, or where I was working and how it was going. I really made a fundamental shift to craft my own "joy pie," my own personal strategic plan, which [asked] what will make my life filled with meaning and purpose for the next 10 years. What does that look like for me? "And I had never done that in my whole career. I had built lots of business plans but I had never actually turned it internal. So I mapped out on a circle how I want to spend my energy and time for the next 10 years. What was important to me in that; what would my legacy be? What would bring me joy? "On that pie wound up things like: do work that reduces suffering, creates joy. Become a Pilates guru. (I'm a washed-up ballerina, so making sure I was still dancing or moving, or having that physical outlet was incredibly important). Be the friend I want to have. I was working so long, 12- to 14-hour days with a 45-minute commute, that I was the sloppy friend—forgetting my friends' birthdays or not showing up. And let's not forget, these are the people coming to your funeral. Being present with my family—I know we use that word a lot ["present"]. I would just say it is so easy to overrun family time with your phone or just take that one extra call or do that one more thing. Now I'm very cognizant of modeling to my kids: put it down, turn the ringer off, and we're not going to have our phones at dinner or at family time. We're going to play ping-pong instead." Thanks for reading, and I'll see you on June 12! This is a preview of Access Health—Tap here to get this newsletter delivered straight to your inbox.
Newsweek
01-05-2025
- Health
- Newsweek
Access Health: Cancer Research's Golden Age Is On Shaky Ground
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Newsweek is hosting a virtual panel discussion "Health Care and AI Governance: Making it Safe, Smart and Scalable," on May 20 at 2:15 p.m. Click here to register for free. I hope to see you there! Today is May 1, the first day of National Cancer Research Month. For this special edition of Access Health, I connected with some of the nation's leading oncology experts and asked them to take us into their world. I found good news and bad news on this foray. I'll start with the good news. There's an undeniable excitement in the field of cancer research right now. In some of my conversations, that excitement transcended into giddiness. Scientists who have dedicated their careers to this work are calling the current moment a "golden age," "something we've only dreamed of," "science-fiction" brought to life. "We are at an exciting time to unveil cancer like it has never been unveiled before, down to the molecular level," said Dr. Craig Eagle, chief medical officer of the precision-oncology company Guardant Health. Both biological and technological advancements have brought us to this period of rapid advancement and unrivaled diagnostic precision, according to Dr. Stephan Hahn, former commissioner of the FDA and current CEO of Harbinger Health, an early cancer detection company. "When I started in oncology 40 years ago, if you had said, 'I'm going to draw a tube of blood and find circulating tumor DNA in the blood,' they would have laughed you out of the room," Hahn told me. "That just wasn't a thing." Now, it is a thing. (Keep reading—we'll unpack some advancements in liquid biopsy and cancer screening in the next section.) By undertaking feats that were once considered impossible, like sequencing an entire human genome, cancer researchers have deepened their understanding of the disease in its many forms. And by investing in more precise testing methods to identify those many cancers, they've been able to deploy more targeted therapies. Recent cancer research has made it easier to screen for and treat certain cancers. Scientists told me that this wouldn't be possible without advancements in machine learning and AI. We now have the capability to search for answers in a much larger pool of genetic information and treatment outcomes, but without the right tech, that would be like searching for a needle in a haystack. This year provides unrivaled conditions for cancer research, as our deepening understanding of the disease coincides with the rising capabilities of AI. But certain headwinds are threatening that hard-earned progress, according to Dr. Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy and former CEO of the American Cancer Society. Knudsen called me April 7 from the Parker Institute's annual retreat, which brings together scientists and venture capitalists from around the world to analyze advancements in the field and translate them into patient testing and company formation. She, too, described a whirlwind of excitement as "brilliant discoveries" are being made. But she also described a rising sense of urgency in the field to ensure that these discoveries aren't lost. "The science is growing at this incredibly strong pace," Knudsen said, "but the market's not been ready to accept this number of discoveries and get them the capitalization that's needed in order to get clinical trials up on the ground." Although the cancer mortality rate in the U.S. is improving, diagnoses are on the rise. Meanwhile, the federal government has threatened cancer research funding—a move that Knudsen called "a real concern to almost everyone in this room." The shortage of capital for life sciences, including cancer therapeutics companies, is already a limiting factor, she told me. Without NIH funding, Knudsen fears trouble: "I don't think there's any one organization or foundation that can replace the role of the US government." SpotItEarly uses a combination of scent dogs and AI to detect cancer in patients' breath samples. Above, a beagle sniffs breath samples. SpotItEarly uses a combination of scent dogs and AI to detect cancer in patients' breath samples. Above, a beagle sniffs breath samples. SpotItEarly Essential Reading Here are a few oncology research advancements that you should know before we get into them, take five minutes to fill out this surveyand let me know how you're liking Access Health! Immunotherapy could help cancer patients with the MMRd gene to avoid surgery, radiation or chemotherapy, according to the results of a clinical trial led by Memorial Sloan Kettering Cancer Center. The trial included 103 patients with several types of stage 1-3 cancer, treating them with Jemperli, a checkpoint inhibitor made by GSK. Eighty percent of patients did not require more aggressive treatments—previously standard for their types of cancer—after six months on the new finding, presented at AACR and published in NEJM on Sunday, builds upon a previous study that used the same drug to treat 100 percent of rectal cancer patients in their trial— in other words, each and every patient's tumor vanished. By extending the study, researchers have proven that the drug can kill other types of cancers as 5-10 percent of rectal tumors and 2-10 percent of other solid tumor cancers in the sample (including esophageal, colon and prostate cancers) are believed to be related to the MMRd gene. "These results could change how we treat some cancers," said Dr. Luis Diaz Jr., head of the division of solid tumor oncology at MSK. "Current treatments like surgery, radiation, and chemotherapy can seriously affect quality of life." The trial included 103 patients with several types of stage 1-3 cancer, treating them with Jemperli, a checkpoint inhibitor made by GSK. Eighty percent of patients did not require more aggressive treatments—previously standard for their types of cancer—after six months on the new finding, presented at AACR and published in NEJM on Sunday, builds upon a previous study that used the same drug to treat 100 percent of rectal cancer patients in their trial— By extending the study, researchers have proven that the drug can kill other types of cancers as 5-10 percent of rectal tumors and 2-10 percent of other solid tumor cancers in the sample (including esophageal, colon and prostate cancers) are believed to be related to the MMRd gene. said Dr. Luis Diaz Jr., head of the division of solid tumor oncology at MSK. "Current treatments like surgery, radiation, and chemotherapy can seriously affect quality of life." Harbinger Health unveiled new data at AACR showing promising results for its blood-based multi-cancer early detection (MCED) platform. "I think these tests should ultimately become part of a [routine] check-up so that people can be certain that they are well, and if they are unwell, things can be done sooner rather than later. The nature of our test is that it is not purely for specialists, but can also be used in the community, so primary care docs can use it to support their patients."Hahn: "100 percent, that's the vision. No one bats an eye at getting cholesterol checked every three months as you intervene to make sure it's getting better. No one even thinks about it—and that's the way this should become." so that people can be certain that they are well, and if they are unwell, things can be done sooner rather than later. The nature of our test is that it is not purely for specialists, but can also be used in the community, so primary care docs can use it to support their patients."Hahn: "100 percent, that's the vision. No one bats an eye at getting cholesterol checked every three months as you intervene to make sure it's getting better. The precision-oncology company Guardant Health is also making strides in blood-based cancer screening. At this week's conference, the company presented 18 abstracts highlighting its Guardant Infinity platform, which integrates blood and tissue testing to provide a comprehensive view of a patient's cancer. This approach captures changes in gene expression, DNA structure and methylation—allowing clinicians to track how cancer develops and responds to treatment over Craig Eagle, Guardant Health's chief medical officer, summarized the most relevant findings for me. Here's one that stood out: Guardant's platform has been able to identify cancer signals of origin, which show clinicians where to look for trouble after patients receive a positive test. New data presented at AACR revealed a more than 90 percent ability to identify the first two cancer "hot spots" in a patient. At this week's conference, the company presented 18 abstracts highlighting its Guardant Infinity platform, which integrates blood and tissue testing to provide a comprehensive view of a patient's cancer. This approach captures changes in gene expression, DNA structure and methylation—allowing clinicians to track how cancer develops and responds to treatment over Craig Eagle, Guardant Health's chief medical officer, summarized the most relevant findings for me. Here's one that stood out: Guardant's platform has been able to identify cancer signals of origin, which show clinicians where to look for trouble after patients receive a positive test. New data presented at AACR This at-home breath-collection kit from SpotItEarly is improving access to pre-screenings for multiple types of cancer by using a unique combination of dogs and AI. Nature study involving 1,386 participants. It also identified 14 other cancer types that it wasn't specifically trained to detect with 81.8 percent sensitivity—suggesting broader potential for this screening method. Pulse Check Dr. Boris Pasche is the president and CEO of the Barbara Ann Karmanos Cancer Institute and chair of the department of oncology at Wayne State University, both based in Detroit. Dr. Boris Pasche is the president and CEO of the Barbara Ann Karmanos Cancer Institute and chair of the department of oncology at Wayne State University, both based in Detroit. Dr. Boris Pasche Dr. Boris Pasche is the president and CEO of the Barbara Ann Karmanos Cancer Institute and chair of the department of oncology at Wayne State University, both based in Detroit. Before joining Karmanos, Pasche led Wake Forest Baptist's cancer center and chaired its cancer biology department. A pioneer in cancer genetics, he discovered a gene variation linked to cancer risk and co-invented an FDA-approved device for the treatment of patients with advanced hepatocellular carcinoma who fail first- and second-line therapies. As both an executive and a cancer researcher, Pasche is tuned into the science and logistics behind oncology research. I was excited to connect with him this week for a pulse check. Is there a breakthrough or innovation in oncology research that you wish was getting more attention? Fill us in! In the past decade, there has been an impressive number of lifesaving innovations in cancer research and treatment. Some examples include CAR T-cell therapy, which uses a patient's own T-cells to seek out and destroy cancer cells, and the development of theranostics, which combines diagnosis and treatment using radioactive pharmaceuticals to both identify and precisely target cancer cells. More recently, I am personally very excited about what could be a revolutionary technology that will allow people to undergo cancer treatment in their homes with few side effects. Over more than two decades, my colleagues and I developed a treatment modality using radiofrequency electromagnetic fields to specifically target tumor cells without affecting normal cells. It is the first such treatment FDA-approved for cancer therapy, and because the treatment can be effectively delivered through a handheld device, it can be given at home. Right now, the Therabionic P-1 is only FDA-approved for certain liver cancer patients who have failed more traditional treatments, but we have several ongoing clinical trials that are researching its ability to treat other tumor types, which is very exciting. A promising attribute of this therapy is that patients who have used it have experienced practically no side effects, and it is the first systemic therapy using radiofrequency electromagnetic fields to target cancer at the cellular level, targeting tumor cells while leaving other cells intact. If it proves effective in other tumor types, I expect it to be an effective and side-effect-free weapon against many types of cancer. Which industry trends are you keeping an eye on, and how might they alter cancer researchers' strategies in the future? I am most interested in understanding how to incorporate AI into cancer research and treatment. We don't know for sure what changes it will yield, but it already has a direct application in radiology. For example, it's been shown to recognize specific tumor patterns potentially more quickly and more thoroughly than a human can. A human still needs to verify and certify those results, but we might get an additional level of security and accuracy by using AI to diagnose cancers more completely and accurately. AI is also poised to affect pathology. Pathology is a very complex field, but in cancer, physicians look at patterns of certain cells to try to define precisely where cancer tumors originated. AI is already recognizing patterns typical of certain types of tumors versus others, which is proving beneficial. One great hope is that pathology will get better and better in terms of providing a more exact diagnosis. Many patients diagnosed elsewhere seek second opinions at Karmanos. We know pathologists providing second opinions change the initial diagnosis received elsewhere 1-35 percent of the time. That is a good reason to pursue a second opinion, but it is also a large error rate, so we are eager to learn how AI might be harnessed to improve initial diagnosis. C-Suite Shuffles UnitedHealth Group made two changes to its leadership team on Tuesday. The company promoted Dr. Patrick Conway , who currently helms Optum Rx, to CEO of the entire Optum enterprise. Heather Cianfrocco —Optum's current CEO—was named executive vice president of governance, compliance and information security for UnitedHealth Group. Encompass Health tapped Patrick Tuer to serve as its first COO . He has held various leadership positions, including group president and regional president, since joining the company in 2018. Encompass is the largest owner and operator of inpatient rehabilitation hospitals in the U.S. Neil Cowles is the new chief information and technology officer at Kaiser Permanente, based in Oakland, California. He has been working as the health system's chief technology officer since last summer and will lead its IT organization in his new role. Executive Edge Dr. Christopher Flowers is the division head of cancer medicine at MD Anderson Cancer Center, based in Texas. Dr. Christopher Flowers is the division head of cancer medicine at MD Anderson Cancer Center, based in Texas. Dr. Christopher Flowers My running routine has fallen to the wayside recently, but after speaking with Dr. Christopher Flowers on Tuesday, I was itching to lace up my shoes and hit the trails! Flowers is the division head of cancer medicine at MD Anderson Cancer Center, overseeing 16 medical oncology departments, composed of roughly 450 faculty members and 3,000 employees. When we connected, he was here in Chicago for the AACR conference—and started his busy day with a six-mile run along the Lakefront Trail. As a lifelong runner and a health care professional, Flowers prioritizes physical activity, even on busy workdays. Here's a snippet of our conversation, where we discussed how he does it: "As you gain increasing responsibility as a health care executive, it becomes more and more challenging to fit [running] into your daily schedule . I don't have knees that are as good as they were 20 years ago or a schedule that is as permissive as it was 20 years sometimes that 17-mile run turns into a six-mile run, like it did this morning. But it's still great to get out and be able to enjoy the outdoors and to be able to build exercise into your daily habits. That's been one of the key components [of my routine], is that whenever I am traveling, I try to build exercise into the beginning of the day or the end of the day. . I don't have knees that are as good as they were 20 years ago or a schedule that is as permissive as it was 20 years sometimes that 17-mile run turns into a six-mile run, like it did this morning. But it's still great to get out and be able to enjoy the outdoors and to be able to build exercise into your daily habits. That's been one of the key components [of my routine], is that "The other component is trying to build exercise into daily life at work. When I first moved to MD Anderson, I lived a little bit more than a mile away from work, so I walked to work every day and walked home. Now I live about two miles away from work, so I walk to work about once or twice a week and then walk home. But building that exercise into the everyday component of life has really been a critical way to be able to maintain those healthy habits. There's almost nothing that can happen in a busy day, as a health care executive, that isn't gone or released after walking a mile or two home. [Then, you are] actually ready to be present at home with your family with all the stresses of the workday left behind you. I find that many of the challenges and problems that may not have been completely solved during the day, oftentimes get solved on that walk home or walk to work in terms of planning for the day. [Then, you are] actually ready to be present at home with your family with all the stresses of the workday left behind you. I find that many of the challenges and problems that may not have been completely solved during the day, oftentimes get solved on that walk home or walk to work in terms of planning for the day. "Exercise plays a role in essentially every study that we do in cancer care: in helping people to respond better to cancer therapies and preventing people from getting cancer." This is a preview of Access Health—Tap here to get this newsletter delivered straight to your inbox.
